Plasma Fractionation Market on Track to Hit USD 39.7 Billion by 2032, Registering a 5.1% CAGR

Plasma Fractionation Industry Outlook 2024-2032

Summary:

Plasma Fractionation Market Graph

• The global plasma fractionation market size reached USD 25.1 Billion in 2023.
• The market is expected to reach USD 39.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
• North America leads the market, accounting for the largest plasma fractionation market share.
• Immunoglobulins accounts for the majority of the market share in the product segment as Immunoglobulins are essential for treating various immune deficiencies and autoimmune diseases.
• The private sector holds the largest share in the plasma fractionation industry.
• Neurology remains a dominant segment in the market, as neurological disorders are increasing, and immunoglobulin therapies have proven effective in treating conditions like guillain-barre syndrome and multiple sclerosis.
• Hospitals and clinics represents the leading end user segment.
• The growing demand for plasma-derived products is the primary driver of the plasma fractionation market.
• Technological advancements and the increasing number of chronic ailments are reshaping the plasma fractionation market.

Request the sample copy of the report: https://www.imarcgroup.com/plasma-fractionation-market/requestsample

Industry Trends and Drivers:

• Increased Demand for Plasma-Derived Products:

The demand for plasma-derived products like immunoglobulins, clotting factors, and albumin is increasing due to their critical role in treating a variety of medical conditions. For instance, immunoglobulins are essential in managing immune deficiencies and autoimmune diseases, while clotting factors are crucial for patients with hemophilia, preventing life-threatening bleeding episodes. Moreover, albumin is often used in liver disease treatment and surgical procedures for volume expansion and shock management. As these therapies become more widely recognized for their efficacy, especially in cases of chronic and life-threatening conditions, the need for plasma fractionation is contributing to the market growth. This rising demand pushes the industry to enhance the collection, processing, and distribution of plasma products, ensuring that the medical community can meet therapeutic needs.

• Rising Incidence of Chronic Diseases:

The growing prevalence of chronic diseases like autoimmune disorders, respiratory conditions, and infectious diseases is escalating the demand for plasma-derived therapies. Additionally, autoimmune diseases such as rheumatoid arthritis and lupus require long-term treatment with immunoglobulins to modulate the immune response and prevent flare-ups. Similarly, respiratory conditions, particularly those resulting from severe infections, can require plasma-based interventions like albumin or immunoglobulin therapies to support patient recovery. Besides, the COVID-19 pandemic has also highlighted the critical role plasma-derived products can play in combating viral infections. As chronic conditions continue to increase globally, particularly with increasing life expectancy and environmental factors contributing to disease onset, the need for plasma therapies will grow in parallel. This correlation between disease prevalence and plasma-derived product demand underscores the importance of efficient plasma fractionation processes to ensure that patients have timely access to the treatments they need.

• Technological Advancements:

Technological advancements in plasma fractionation have significantly enhanced the efficiency and quality of plasma-derived products. Innovations in purification and separation techniques now allow for better isolation of specific proteins like immunoglobulins, clotting factors, and albumin, increasing the yield and therapeutic value of these products. For example, chromatography methods have become more refined, allowing for purer product output and reduced risk of contamination. Additionally, advancements in cryoprecipitation and ultrafiltration have improved the overall yield of valuable plasma components. These innovations are also expanding the potential applications of plasma-derived therapies beyond traditional uses, opening up possibilities for treating new diseases or improving current treatment protocols. As these technologies continue to evolve, they will increase the availability of plasma-based products and reduce production costs, making these life-saving therapies more accessible to a broader population.

Plasma Fractionation Market Report Segmentation:

Breakup By Product:

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX

Immunoglobulins represent the largest segment, as Immunoglobulins are essential for treating various immune deficiencies and autoimmune diseases.

Breakup By Sector:

• Private Sector
• Public Sector

Based on the sector, the market is bifurcated into the private and public sectors.

Breakup by Application:

• Neurology
• Immunology
• Hematology
• Other Applications

Neurology dominates the market growth, as neurological disorders are increasing, and immunoglobulin therapies have proven effective in treating conditions like guillain-barre syndrome and multiple sclerosis.

Breakup By End User:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes
• 
  

Hospitals and clinics holds the largest market share, as they are the primary settings for administering plasma-derived therapies, resulting in their substantial share of the plasma fractionation market.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position owing to a large market for plasma fractionation driven by advanced healthcare infrastructure, high prevalence of blood disorders, and significant investment in biotechnology and pharmaceuticals.

Top Plasma Fractionation Market Leaders:

The plasma fractionation market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• ADMA Biologics
• Bio Products Laboratory Ltd.
• Boccard
• Grifols, S.A.
• Hemarus Therapeutics Limited
• Intas Pharmaceuticals Limited
• LFB S.A.
• Merck Group
• Octapharma AG
• PlasmaGen BioSciences Pvt. Ltd.
• SK Plasma Co. Ltd.
• Virchow Biotech Private Limited

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.